Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "legacy"

135 News Found

Indian nutraceutical market is expected to touch US $ 18 bn by 2025: Dr R.B Smarta
interviews | November 18, 2021

Indian nutraceutical market is expected to touch US $ 18 bn by 2025: Dr R.B Smarta

The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector


UK authorises first Covid-19 pill
News | November 05, 2021

UK authorises first Covid-19 pill

Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency


NASSCOM CoE-IoT announces winners of Healthcare Innovation challenge
Healthcare | October 01, 2021

NASSCOM CoE-IoT announces winners of Healthcare Innovation challenge

This one-of-a-kind innovation challenge is aimed at addressing the challenges faced by healthcare providers in digital technology adoption


Merck to acquire Acceleron for US $ 11.5 billion
News | October 01, 2021

Merck to acquire Acceleron for US $ 11.5 billion

The acquisition complements and strengthens Merck’s cardiovascular pipeline


Merck and Ridgeback’s molnupiravir offer hope to Covid-19 patients
Biotech | October 01, 2021

Merck and Ridgeback’s molnupiravir offer hope to Covid-19 patients

If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic


AstraZeneca to collaborate with VaxEquity for self-amplifying RNA therapy
Biotech | September 24, 2021

AstraZeneca to collaborate with VaxEquity for self-amplifying RNA therapy

saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level


Indigenous technology will help reduce dependence on imports: Dr Singh
Digitisation | September 03, 2021

Indigenous technology will help reduce dependence on imports: Dr Singh

Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.


Solara announces restoration of CEP for ranitidine hydrochloride
News | July 03, 2021

Solara announces restoration of CEP for ranitidine hydrochloride

Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site


'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.
Interviews | June 10, 2021

'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.

In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview: